Mark your calendar for Thursday 22nd May, 29th May, and 5th June at 3pm BST | 4pm CEST | 10am ET .
Liquid biopsies are transforming cancer care, offering a fast, non-invasive way to detect, monitor, and manage cancer at the molecular level. From early diagnosis to tracking treatment response and resistance, these tools are reshaping real-time, data-driven decisions in oncology.
But are we fully harnessing their potential? Join us for our three-part webinar series, Liquid Biopsy Online, to explore how to improve detection accuracy, expand clinical utility, and accelerate a shift towards a liquid-first future in oncology.
What you’ll gain by attending:
- Insights into the path towards a liquid-first approach in cancer diagnostics
- Practical knowledge on expanding applications – from early detection to treatment monitoring
- Strategies to improve test accuracy, sensitivity, and enhance clinical confidence
**Please note that by registering for the first webinar in the series you will automatically gain access to the second webinar.**
Webinar 1: Beyond The Bench: Transforming Cancer Diagnosis and Treatment Decision Making Through Liquid Biopsies
Thursday 22nd May, at 3pm BST | 4pm CEST | 10am ET
Sponsored by Asuragen
This webinar will discuss how liquid biopsies are advancing molecular cancer analysis through non-invasive means. It will demonstrate the strength of using liquid biopsies to detect molecular relapse early, optimise rare variant detection, and improve clinical workflows for better patient outcomes.
Talk 1: Liquid Biopsy in Solid Tumours
- Umberto Malapelle, Associate Professor in the School of Medicine, University of Naples Federico II
Talk 2: Small But Mighty: Leveraging Exosomes in Liquid Biopsy for Highly Sensitive qPCR Variant Detection
- Kevin Kelnar, Senior Manager, Research & Development, Asuragen
Talk 3: Advancing Liquid Biopsy Technologies: High-Volume CTC Detection for Precision Medicine
- Nikolas Stoecklein, Professor, University of Dusseldorf
Talk 4: Utility of ctDNA in Sarcoma: Challenges and Promising Advances
- Brittany Siontis, Assistant Professor & Medical Oncologist, Mayo Clinic
Webinar 2: From Detection to Decision: Liquid Biopsies for Treatment Monitoring
Thursday 29th May, at 3pm BST | 4pm CEST | 10am ET
Sponsored by Qiagen
Join us to explore the evolving role of liquid biopsies in cancer care, featuring cutting-edge advances in cfDNA multi-omics, clinical applications in metastatic breast cancer and dynamic risk stratification.
Talk 1: Cracking the Code of cfDNA: Integrating Fragmentomics into Liquid Biopsies
- Alexandra Clipson, Deputy Team Leader, Nucleic Acid Biomarkers Team, Cancer Research UK
Talk 2: Liquid Biopsies to Guide Treatment Decisions for Metastatic Breast Cancer
- Jenna Canzoniero, Assistant Professor, Johns Hopkins University
Talk 3: Dynamic Risk Stratification using Circulating HPV DNA
- Scott Bratman, Associate Professor, University of Toronto
Webinar 3: Expanding Liquid Biopsy Applications in Clinical Care
Thursday 5th June, at 3pm BST | 4pm CEST | 10am ET
How can we move toward a liquid-first approach in cancer diagnostics? This webinar will explore the future of liquid biopsies, including their utility for multi-cancer early detection (MCED), advancing treatment selection, and patient monitoring.
Talk 1: Determination of Tumour PSMA Expression and Lutetium-PSMA Response in Men with Prostate Cancer Using a Novel Epigenomic Liquid Biopsy Platform
- Jacob Berchuck, Assistant Professor, Emory University
Talk 2: The Clinical Potential of Liquid Biopsies for Effective Treatment Selection and Resistance Monitoring in Metastatic Cancers
- Hai Tran, Associate Professor, MD Anderson Cancer Center
Talk 3: Boosting Liquid Biopsies using Multi-Modal Integration
- Florent Mouliere, Team Leader, Cancer Research UK
Don’t miss this opportunity to stay at the forefront of precision oncology and register now!
